D. E. Shaw & Co., Inc. Astrazeneca PLC Call Options Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$76.67 - $87.62 $881,705 - $1.01 Million	11,500 Added 68.45%	28,300 $2.21 Million
Q2 2024 Aug 14, 2024	BUY	$66.81 - $80.83 $1.12 Million - $1.36 Million	16,800 New	16,800 $1.31 Million
Q1 2023 May 15, 2023	BUY	$63.15 - $71.6 $1.05 Million - $1.19 Million	16,600 New	16,600 $1.15 Million
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $1.86 Million - $2.03 Million	33,400 Added 44.89%	107,800 $6.47 Million
Q2 2021 Aug 16, 2021	BUY	$48.42 - $60.18 $3.6 Million - $4.48 Million	74,400 New	74,400 $4.46 Million
Q1 2021 May 17, 2021	SELL	$47.16 - $54.44 $4 Million - $4.62 Million	-84,900 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$48.52 - $58.02 $4,852 - $5,802	-100 Reduced 0.12%	84,900 $4.24 Million
Q3 2020 Nov 16, 2020	SELL	$53.07 - $61.1 $169,824 - $195,520	-3,200 Reduced 3.63%	85,000 $4.66 Million
Q4 2019 Feb 14, 2020	BUY	$42.46 - $50.46 $3.74 Million - $4.45 Million	88,200 New	88,200 $4.4 Million

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $205B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.